CN103932186B - A kind of bifidus longum bb microcapsule and preparation method thereof - Google Patents
A kind of bifidus longum bb microcapsule and preparation method thereof Download PDFInfo
- Publication number
- CN103932186B CN103932186B CN201410162678.XA CN201410162678A CN103932186B CN 103932186 B CN103932186 B CN 103932186B CN 201410162678 A CN201410162678 A CN 201410162678A CN 103932186 B CN103932186 B CN 103932186B
- Authority
- CN
- China
- Prior art keywords
- microcapsule
- bifidus longum
- polysaccharide
- bifidus
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 150000004676 glycans Chemical class 0.000 claims abstract description 32
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 32
- 239000005017 polysaccharide Substances 0.000 claims abstract description 32
- 241000894006 Bacteria Species 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 23
- 230000001954 sterilising effect Effects 0.000 claims abstract description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 16
- 108010046377 Whey Proteins Proteins 0.000 claims description 15
- 102000007544 Whey Proteins Human genes 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 235000021119 whey protein Nutrition 0.000 claims description 15
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 13
- 235000010413 sodium alginate Nutrition 0.000 claims description 13
- 239000000661 sodium alginate Substances 0.000 claims description 13
- 229940005550 sodium alginate Drugs 0.000 claims description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 239000012460 protein solution Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 6
- 229920000084 Gum arabic Polymers 0.000 claims description 5
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000000205 acacia gum Substances 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012267 brine Substances 0.000 claims description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 238000007711 solidification Methods 0.000 claims description 3
- 230000008023 solidification Effects 0.000 claims description 3
- 239000002689 soil Substances 0.000 claims description 2
- 238000011146 sterile filtration Methods 0.000 claims description 2
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 26
- 238000004108 freeze drying Methods 0.000 abstract description 15
- 238000003860 storage Methods 0.000 abstract description 10
- 230000002496 gastric effect Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 230000004083 survival effect Effects 0.000 abstract description 8
- 241000186000 Bifidobacterium Species 0.000 abstract description 5
- 238000001035 drying Methods 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 2
- 238000001556 precipitation Methods 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 description 13
- 235000013618 yogurt Nutrition 0.000 description 13
- 239000012530 fluid Substances 0.000 description 12
- 239000011162 core material Substances 0.000 description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000007669 thermal treatment Methods 0.000 description 2
- 241000203716 Actinomycetaceae Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a kind of bifidus longum bb microcapsule and preparation method thereof, its core is bifidus longum bb BBMN68, wall material comprises metaprotein and polysaccharide, core is mixed with the wall material after sterilizing, adopt the method for orifice-precipitation bath and vacuum lyophilization, prepare freeze-drying bifidus longum bb microcapsule, the bacteria containing amount of microcapsule is 10
8-10
11cFU/g.After these microcapsule preserve 6 months at ambient temperature, bifidobacteria is still 10
8more than CFU/g; Freeze-drying microcapsule granule by gastric environment can be more viable count arrive enteron aisle, and in enteron aisle, bifidus bacillus major part to be discharged.Bifid bacterium microcapsule of the present invention is lyophilized form, for bifidus bacillus BBMN68 provides the environment of low temperature, vacuum and drying, well solve that it is not acidproof, not oxytolerant and the not easily shortcoming such as survival, and there is the longer quality guaranteed period, the advantage of good storage stability and enteric solubility.
Description
Technical field
The present invention relates to a kind of microcapsule product, be specifically related to a kind of bifidus longum bb BBMN68 microcapsule and preparation method thereof.
Background technology
Bifidus bacillus belongs to Actinomy cetaceae genus bifidobacterium, and the bacterial classification being applied to production when forefathers source bifidus bacillus comprises bifidumbacterium bifidum (B.bifidum), bifidobacterium adolescentis (B.adolescentis), bifidobacteria infantis (B.infantis), bifidus longum bb (B.longum) and bifidobacterium breve (B.breve).Bifidus bacillus is without brood cell, and Individual Size is 0.5 ~ 1.3 μm × 1.5 ~ 8 μm, and representative configuration is the shaft-like of end furcations.Its colony colour is cream-colored to white, and shape dome, quality softness is flexible, smooth surface, and edge is complete.Bifidus bacillus obligate anaerobic, optimum growth temperature 37 ~ 41 DEG C, minimum growth temperature 25 ~ 28 DEG C, maximum growth temperature 43 ~ 45 DEG C, initial growth optimum pH 6.5 ~ 7.0, pH value less than 5.0 or more than 8.0 does not grow, and sour environment (pH≤5.5) is unfavorable to thalline survival.
Bifidus bacillus is as the typical probiotic bacterium of one, and research has confirmed there is multinomial physiological hygiene function to human body, as improved human body stomach, trophism, anti-ageing, antitumor action and improving immunizing power etc.Researching and practicing shows, bifidus bacillus is physiological bacterium useful to body in humans and animals enteron aisle, and its quantity is dynamic change trend with change of age, and closely bound up with the good health and a long life of people.Due to reasons such as environmental pollution, abuse of antibiotics, chemicotherapies, the quantity of bifidus bacillus in human intestinal is declined, thus causes the healthy state of human body to decline.Therefore can by research and development bifidus bacillus goods, external source takes in bifidus bacillus, increases the quantity of bifidus bacillus in human intestinal, thus improves the health level of human body.
The research of current China to bifidus bacillus is also in ascent stage, and product development is few, at present mainly bifidobacterium yoghurt.Because bifidus bacillus requires higher to nutritional condition, very responsive to oxygen, poor to the resistibility of low ph value, the features such as active maintenance is more difficult make the practical application of bifidus bacillus be subject to certain restrictions.Especially its acidproof, oxygen resistence extreme difference of bifidus longum bb BBMN68, and beneficial effect to be produced to human body, must a large amount of survival bacterium be still had to arrive enteron aisle and be colonizated on intestinal mucosa after by gastric environment.But due to the germicidal action of hydrochloric acid in gastric juice, viable count can significantly decline in the process, in Switzerland and international Ru Lian stdn council prescribed product, the viable count of bifidus bacillus is greater than 10
6cFU/mL or g.Therefore further must protect bifidus bacillus, can survive as much as possible and arrive enteron aisle and play a role.
For this reason, emphasis of the present invention is improve the survival rate of bifidus bacillus in production application and storage.The present invention adopts microcapsulary to be combined with lyophilize, has prepared a kind of freeze-drying enteric solubility microcapsule being convenient to preserve and apply.
Microcapsulary utilizes polymer substance that is natural or synthesis, solid, liquid, gas carried out the microdisplay package technology embedded.The core material of unstable properties, as wall material, embeds, seals up by the natural or synthetic high polymer matter that namely utility is more stable, and the original character of protection core, under certain condition, wall material breaks or dissolves, and namely core discharges and play function.The present invention with protein (whey-protein or gelatin) and polysaccharide (sodium alginate, chitosan or gum arabic) for microcapsule wall material embeds bifidus longum bb BBMN68, and add cryoprotectant and thalline and extraneous poor environment are separated, and ensure that viable bacteria as much as possible arrives intestinal colonisation and plays effect; By freezing dry process, in microcapsule, moisture rapid evaporation falls to make it to keep lower moisture content, is convenient to store and application.
Summary of the invention
Bifidus longum bb microcapsule that the object of this invention is to provide a kind of freeze-drying and preparation method thereof.
To achieve these goals, the present invention adopts following technical scheme:
A kind of bifidus longum bb microcapsule, the wall material of these microcapsule comprises metaprotein and polysaccharide, and core is bifidus longum bb BBMN68; Core is mixed with the wall material after sterilizing, adopts the method for orifice-precipitation bath and vacuum lyophilization, obtain bifidus longum bb microcapsule; Wherein, the mass ratio of above-mentioned metaprotein and polysaccharide is 1-5:1, and the bacteria containing amount of microcapsule is 10
8-10
11cFU/g.
Bifidus longum bb BBMN68 is separated the ight soil of Zi Bama county long lived elder, and be preserved in DSMZ of Institute of Micro-biology of the Chinese Academy of Sciences, preserving number is CGMCC2265.
A kind of preferred bifidus longum bb microcapsule, its wall material also comprises lyophilized vaccine, and the mass ratio of lyophilized vaccine, metaprotein and polysaccharide is 12.5-25:1-5:1.Lyophilized vaccine effectively can protect the activity of bifidus bacillus in freezing dry process, to reach the effect improving the number of active bifid bacteria amount.
Above-mentioned metaprotein is denatured whey protein or metagelatin, is preferably the whey-protein of sex change; Above-mentioned polysaccharide is sodium alginate, chitosan or gum arabic, is preferably sodium alginate; Above-mentioned lyophilized vaccine is glycerine, trehalose or skim-milk, is preferably glycerine.
Above-mentioned microcapsule are spherical, and its diameter is 0.5-5mm.
A preparation method for above-mentioned bifidus longum bb microcapsule, comprises the steps:
(1) bifidus longum bb of activation is cultivated, fermented liquid is centrifugal, and use brine thalline, obtain bifidus longum bb wet thallus;
(2) by the pH regulator of protein solution to 7.0-8.5, heating make its abundant sex change, then it is mixed with polysaccharide soln, sterilizing, obtains protein-PS mixing solutions; By the pH regulator of calcium chloride solution to 6.0-8.5, sterilizing;
(3) aseptically, the wet thallus that step (1) obtains is joined in the protein-PS mixing solutions that step (2) obtains, be added dropwise in calcium chloride solution after mixing and solidify, sterile filtration, washing, obtain moistening microcapsule;
(4) moistening microcapsule lyophilize step (3) obtained, obtains bifidus longum bb microcapsule.
Wherein:
Activation in step (1) refers at 36.5-37.5 DEG C, cultivates 12h, and repeat Secondary Culture 2-3 time by frozen bifidus longum bb liquid medium within.Wherein, go down to posterity two kinds of vaccination ways: the nutrient solution of the bacterium colony good by picking shape on flat board or directly absorption bifidus longum bb is to new liquid nutrient medium.Then, at 36.5-37.5 DEG C of temperature, cultivate 15h by the bifidus longum bb liquid medium within of activation, by collected by centrifugation thalline.
Aforesaid liquid substratum is preferably MRS liquid nutrient medium.
Albumen or polysaccharide first join in deionized water in (2) by step, stir, and in order to ensure dissolving hydration completely, usually selecting 4 DEG C of hold over night, albumen or polysaccharide are dissolved completely, and next day, balance was to room temperature, obtained albumen or polysaccharide soln.Wherein, room temperature is generally 15-30 DEG C, is preferably 25 DEG C; When the pH value of Function protein solution, preferably use the NaOH of 1mol/L.
In step (2), the concentration of protein solution is 2.0wt%-8.0wt%; The concentration of polysaccharide soln is 1.0wt%-10.0wt%; The concentration of calcium chloride solution is 1.0wt%-5.0wt%.
A kind of preparation method of preferred bifidus longum bb microcapsule; also containing lyophilized vaccine in polysaccharide soln described in step (2); wherein the concentration of polysaccharide and lyophilized vaccine is respectively 1.0wt%-10.0wt% and 30.0wt%-50.0wt%; this solution is obtained by preparation in the aqueous solution that polysaccharide is dissolved in lyophilized vaccine; as glycerine solution dissolves polysaccharide, obtain the final solution simultaneously containing glycerine and polysaccharide.
Described in step (2), the temperature of heating is 60-90 DEG C, and the time is 15-45min, makes the complete sex change of albumen by thermal treatment.
In step (2), the protein solution after sex change is mixed with polysaccharide soln, at 100 DEG C of sterilizing 30min.
In step (2), preferably use the HCl of 1mol/L by the pH regulator of calcium chloride solution to 7.0-8.5, then at 121 DEG C of sterilizing 20min.
In step (3), the time of solidification is 15-60min.
Use orifice device to be vertically added drop-wise in calcium chloride coagulation bath by thalline suspension in step (3) and make microlayer model, form bifid bacterium microcapsule after solidification, this orifice device is dropper or syringe.
Washing in step (3) is for using brine microcapsule.
The concentration of above-mentioned physiological saline is 0.9wt%.
In step (4), the cryodesiccated time is 24-48h.
Beneficial effect of the present invention is as follows: compared with routine techniques, using metaprotein and polysaccharide as wall material in the present invention, protein denaturation is made by thermal treatment, make it on the basis keeping original film-forming properties, emulsifying property and gel-type, also there is following characteristic: after (1) sex change, the peptide chain of albumen launches, water-soluble increase; (2) under normal temperature, the solution viscosity of whey-protein or gelatin is lower, and after distortion, the secondary structure of albumen is launched, and intramolecular active group leaks cruelly, and viscosity increases.(3) albumen after sex change is mutually assembled but is not formed gel, and these protein aggregates can as the fundamental unit of epoxy resin three-dimensional net structure.
The bifidus longum bb BBMN68 that microcapsule of the present invention embed is low especially for the tolerance of acid and oxygen, more not easily survives.The present invention is by improving the composition of wall material; in the structure that metaprotein is formed; add composite polysaccharide; feasible one-tenth network cross-linked structure; and during active bacteria is embedded in; realize the protection to active substance and slowly-releasing; adopt vacuum freeze-drying method simultaneously; and add lyophilized vaccine; improve survival rate and the package stability of cell after bifid bacterium microcapsule vacuum lyophilization; make the quality guaranteed period of the freeze-drying bifidus longum bb BBMN68 microcapsule finally obtained elongated, the preservation under room temperature phase can reach more than 50 days, even can reach more than 6 months.Bifidus longum bb microcapsule of the present invention are direct-edible also be can be applicable in other food, and through gastro-intestinal digestion, most of thalline can discharge at enteron aisle by microcapsule, reaches effect of probiotic supplemented.
Accompanying drawing explanation
Fig. 1 is the viable count change curve of bifidus longum bb microcapsule in Yoghourt in embodiment 1 and 2.
Fig. 2 is the stomach juice-resistant detection curve of bifidus longum bb microcapsule in simulated gastric fluid in embodiment 1 and 2.
Fig. 3 is the absorbancy-time curve of bifidus longum bb microcapsule in simulated intestinal fluid in embodiment 1 and 2.
Fig. 4 is the release profiles of bifidus longum bb microcapsule in simulated intestinal fluid in embodiment 1 and 2.
Fig. 5 is bifidus longum bb microcapsule storage tolerance test curve at ambient temperature in embodiment 1 and 2.
Embodiment
Below in conjunction with the drawings and specific embodiments, the present invention will be described in detail, but protection domain not thereby limiting the invention.
The MRS liquid nutrient medium used in following embodiment can be buied from commercial channels.
Raw material in following embodiment is food grade, has no side effect, and edible have security and nutritive value.
Embodiment 1 with bifidus longum bb BBMN68 for core, with sodium alginate and whey-protein for wall material
(1) preparation of bacterial strain: in Bechtop, the bacterium liquid of bifidus longum bb BBMN68 frozen for 0.1ml is inoculated in 10mlMRS liquid nutrient medium, anaerobism pipe is used at 36.5-37.5 DEG C of temperature, to cultivate 12h in climatic chamber, repeat to go down to posterity 2-3 time, obtain the bifidus longum bb activated.
By the bifidus longum bb of activation by 0.1% volume ratio be inoculated in 250mlMRS liquid nutrient medium, be placed in climatic chamber, at 36.5-37.5 DEG C of temperature, cultivate 15h, the centrifugal 15min of 4500rpm collects thalline.Then use 0.9% brine thalline, centrifugal 15min under 4500rpm, after repeated washing 2 times, obtain the bifidus longum bb wet thallus of pureed.
(2) whey-protein is joined in deionized water, use magnetic stirring apparatus, 2h is stirred under room temperature (about 25 DEG C), then 4 DEG C of environment hold over night are placed in, to guarantee that whey-protein dissolves hydration completely, next day, balance was to room temperature, regulated its pH to 8.0 with 1mol/LNaOH, obtain the lactoalbumin soln of 8wt%, at 80 DEG C, heating in water bath 30min makes its abundant sex change.
Joined by sodium alginate in deionized water, stirred at ambient temperature is to dispersed, and hold over night in 4 DEG C of environment, next day, balance was to room temperature, obtained the sodium alginate soln of 4wt%.
By the lactoalbumin soln of sex change and polysaccharide soln mixing, wherein the mass ratio of whey-protein and sodium alginate is 1:1, and magnetic agitation makes it mix, sterilizing 30min in 100 DEG C of boiling water baths, stand-by as wall material.
(3) prepare the calcium chloride solution of 3wt%, regulate its pH value to 6.0 with 1mol/LHCl, 121 DEG C of sterilizing 20min, stand-by.
(4) in Bechtop, the centrifugal thalline obtained is joined in wall material, careful stirring makes to mix, and avoids entering bubble.Under the effect of magnetic stirring apparatus, draw above-mentioned mixed solution with 2ml asepsis injector, in vertical instillation calcium chloride coagulation bath, namely form microcapsule granule.Wet capsule solidifies 30min in calcium chloride solution, with aseptic sieved filter, with 0.9% stroke-physiological saline solution washing 2-3 time, obtains moistening microcapsule.
(5) by moistening microcapsule lyophilize 24-48h in vacuum freeze drier, obtain the bifidus longum bb microcapsule of freeze-drying, its bacteria containing amount is about 10
10cFU/g.
Embodiment 2 with bifidus longum bb BBMN68 for core, with sodium alginate, whey-protein and glycerine for wall material
Polysaccharide soln is obtained by preparation in the aqueous glycerin solution that polysaccharide is dissolved in 50wt%, and in the finished product, the mass ratio of glycerine, sodium alginate and whey-protein is 12.5:1:1, and other concrete preparation method is with above-described embodiment 1.
Embodiment 3
Concrete preparation method is with embodiment 2, but sodium alginate is dissolved in the aqueous glycerin solution of 50wt%, wherein the mass ratio of glycerine and sodium alginate is 25:1, it is mixed with the whey-protein of 8wt%, and in the finished product, the mass ratio of glycerine, whey-protein and chitosan is 25:5:1.
Embodiment 4
Concrete preparation method is with embodiment 1, but by the pH regulator to 7.0 of 8wt% lactoalbumin soln, and be mixed to get protein-PS mixing solutions with the chitosan solution of 3wt%, wherein the mass ratio of whey-protein and chitosan is 5:1, and the bacteria containing amount of microcapsule is about 10
8cfu/g.
Embodiment 5
Concrete preparation method is with embodiment 1, but by the pH regulator to 8.5 of the gelatin solution of 4wt%, and be mixed to get protein-PS mixing solutions with the gumwater of 5wt%, wherein the mass ratio of gelatin and gum arabic is 2:1, and the bacteria containing amount of microcapsule is about 10
11cfu/g.
In addition; in other embodiments; wall material can also be the composite of other polysaccharide (as chitosan, gum arabic), other albumen (as gelatin) and other freezing drying protective agents (as trehalose, skim-milk etc.), is not limited to enumerating in above-described embodiment.
The performance evaluation of embodiment 6 bifidus longum bb microcapsule
The bifidus longum bb microcapsule that above-described embodiment prepares are evaluated in accordance with the following methods:
1. the application of bifidus longum bb microcapsule in Yoghourt
The freeze-drying bifid bacterium microcapsule that above-described embodiment 1,2 obtains to be added in Yoghourt after certain hour, removing Yoghourt, and with 0.9% normal saline flushing microcapsule, microcapsule are complete with lyolysis capsule of opening one's purse, dilution certain multiple, select appropriate dilution 37 DEG C of cultivation 48h in MRS solid medium, Heng Gaite counting process is adopted to count, again with to add in Yoghourt freeze-drying microcapsule quality and obtain the quantity of bifidus bacillus in every gram of Yoghourt through converting, determine the package stability of microcapsule in the Shelf-Life of Yogurt.Wherein, liquid of opening one's purse consists of 0.1mol/L Sodium phosphate dibasic, 0.05mol/L citric acid, pH7.25.
Through measuring, the viable count change curve of described microcapsule in the Shelf-Life of Yogurt as shown in Figure 1.As shown in Figure 1, two kinds of microcapsule are in the Shelf-Life of Yogurt (4 DEG C, 21 days), and viable count is all on a declining curve, with the product prepared by the wall material containing glycerine, at the viable count of storage after 21 days 0.8 order of magnitude higher than the product prepared by sodium alginate-whey-protein wall material.And as the active added ingredients of the bifidus bacillus in Yoghourt with nutritive value, colony number reaches 10
6every gram or every milliliter of its effect of competence exertion, namely the storage number of days of bifid bacterium microcapsule in Yoghourt prepared for wall material with sodium alginate-whey-protein is 18 days, and is 21 days with the storage number of days of bifid bacterium microcapsule in Yoghourt that sodium alginate-whey-protein-glycerine is prepared for wall material.
2. the stomach juice-resistant of bifidus longum bb microcapsule detects
The freeze-drying bifid bacterium microcapsule 0.1g obtained in Example 1,2, add in 5ml simulated gastric fluid (pH1.2), be placed in 37 DEG C of insulations, take out every 1h in 3h, with sterile saline washing to neutral, with opening one's purse, liquid dissolves, and measures the viable count of bifidus bacillus, and compares with the freeze-dried vaccine powder do not embedded.
Through measuring, the survival condition of described microcapsule in simulated gastric fluid as shown in Figure 2.As shown in Figure 2, along with the prolongation in treatment time, the survival number of thalline in simulated gastric fluid reduces gradually.After simulated gastric fluid process 3h; do not embed thalline all dead; and two kinds of freeze-drying microcapsule number of viable levels are respectively 7.9 and 8.4, illustrate that the bifid bacterium microcapsule through embedding has good stomach juice-resistant ability, indicate the necessity of bifidus bacillus being carried out to microcapsule protection.
3. the enteric solubility of bifidus longum bb microcapsule detects
PH is regulated to be 7.4 by processing the NaOH solution dripping 0.05mol/L in the simulated gastric fluid after 3h in embodiment 1,2, add 5ml simulated intestinal fluid, in constant-temperature shaking incubator at the temperature of 37 DEG C, dissolve with the concussion of the rotating speed of 150rpm, in 6h, get 1ml intestinal juice dilution counting every 1h and measure the absorbancy of intestinal juice at 600nm place.
Through measuring, the dissolving situation of described microcapsule in simulated intestinal fluid as shown in Figure 3 and Figure 4.As shown in Figure 3, along with the prolongation in treatment time, after microcapsule process 1 hour in simulated intestinal fluid, light absorption value rises rapidly, and within 1 ~ 3 hour, slightly rise, after 3 hours, light absorption value is basicly stable.As can be seen from Fig. 4 also, process 1 hour in simulated intestinal fluid after, in intestinal juice, the quantity of bifidus bacillus increases rapidly, reaches 10
6~ 10
7cFU/g, after 3 hours, the bifidobacteria in intestinal juice tends towards stability, and its result is corresponding with light absorption value result.Illustrate that this bifid bacterium microcapsule has good enteric solubility, in enteron aisle, bifidus bacillus can be discharged by fater disintegration.
4. the storage tolerance test of bifidus longum bb microcapsule
Under the freeze-drying bifid bacterium microcapsule obtained in embodiment 1,2 being stored in room temperature (25 DEG C) condition, regularly sample, measure viable count, and compare with the freeze-dried vaccine powder do not embedded.
Through measuring, the situation of described microcapsule under room temperature storage condition as shown in Figure 5.As shown in Figure 5, bifidus longum bb microcapsule provided by the invention are preserved at ambient temperature, adding microcapsule prepared by glycerine in its mesospore material, to store thalline amount of survival level after 3 months be 8.8, only have dropped 1.6 orders of magnitude, the requirement to the number of active bifid bacteria in practical application can be met; The microcapsule prepared for wall material with sodium alginate-whey-protein storage after 20 days viable count magnitude drop to less than 6; And contrast without the bifidus bacillus of embedding, after thalline viable count magnitude has dropped to less than 6,1 month after depositing 5 days, just can't detect viable bacteria.It can thus be appreciated that embedding method of the present invention extends the shelf-lives of this product effectively, after especially adding glycerine in wall material, after not only making freeze-drying, initial live bacterial content increases, and also add its storage period.
Above-described embodiment is only be described the preferred embodiment of the present invention; not scope of the present invention is specified; under not departing from the present invention and designing the prerequisite of spirit; the various distortion that those of ordinary skill in the art make technical scheme of the present invention and improvement, all should fall in protection domain that claims of the present invention determines.
Claims (8)
1. bifidus longum bb microcapsule, is characterized in that, the wall material of these microcapsule comprises metaprotein, polysaccharide and lyophilized vaccine, and core is bifidus longum bb BBMN68; Wherein, the mass ratio of described lyophilized vaccine, metaprotein and polysaccharide is 12.5-25:1-5:1, and the bacteria containing amount of microcapsule is 10
8-10
11cFU/g; Described bifidus longum bb BBMN68 is separated the ight soil of Zi Bama county long lived elder, and be preserved in DSMZ of Institute of Micro-biology of the Chinese Academy of Sciences, preserving number is CGMCC2265; Described metaprotein is denatured whey protein or metagelatin; Described polysaccharide is sodium alginate, chitosan or gum arabic; Described lyophilized vaccine is glycerine, trehalose or skim-milk.
2. bifidus longum bb microcapsule according to claim 1, is characterized in that, described metaprotein is preferably the whey-protein of sex change; Described polysaccharide is preferably sodium alginate; Described lyophilized vaccine is preferably glycerine.
3. bifidus longum bb microcapsule according to claim 1 and 2, is characterized in that, described microcapsule are spherical, and its diameter is 0.5-5mm.
4. the preparation method of bifidus longum bb microcapsule described in claim 1, it is characterized in that, concrete grammar comprises the steps:
(1) bifidus longum bb of activation is cultivated, fermented liquid is centrifugal, and use brine thalline, obtain bifidus longum bb wet thallus;
(2) by the pH regulator of protein solution to 7.0-8.5, heating make its abundant sex change, then it is mixed with polysaccharide soln, sterilizing, obtains protein-PS mixing solutions; By the pH regulator of calcium chloride solution to 6.0-8.5, sterilizing;
Also containing lyophilized vaccine in described polysaccharide soln, wherein the concentration of lyophilized vaccine and polysaccharide is respectively 1.0wt%-10.0wt% and 30.0wt%-50.0wt%;
(3) aseptically, the wet thallus that step (1) obtains is joined in the protein-PS mixing solutions that step (2) obtains, be added dropwise in calcium chloride solution after mixing and solidify, sterile filtration, washing, obtain moistening microcapsule;
(4) moistening microcapsule lyophilize step (3) obtained, obtains bifidus longum bb microcapsule.
5. preparation method according to claim 4, it is characterized in that, described in step (2), the concentration of protein solution is 2.0wt%-8.0wt%, and the concentration of polysaccharide soln is 1.0wt%-10.0wt%, and the concentration of calcium chloride solution is 1.0wt%-5.0wt%.
6. preparation method according to claim 4, is characterized in that, described in step (2), the temperature of heating is 60-90 DEG C, and the time is 15-45min.
7. preparation method according to claim 4, is characterized in that, in described step (2), after being mixed with polysaccharide soln by the protein solution after sex change, at 100 DEG C of sterilizing 30min.
8. preparation method according to claim 4, is characterized in that, described in step (3), the time of solidification is 15-60min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410162678.XA CN103932186B (en) | 2014-04-22 | 2014-04-22 | A kind of bifidus longum bb microcapsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410162678.XA CN103932186B (en) | 2014-04-22 | 2014-04-22 | A kind of bifidus longum bb microcapsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103932186A CN103932186A (en) | 2014-07-23 |
| CN103932186B true CN103932186B (en) | 2016-03-30 |
Family
ID=51180272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410162678.XA Expired - Fee Related CN103932186B (en) | 2014-04-22 | 2014-04-22 | A kind of bifidus longum bb microcapsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103932186B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435283B (en) * | 2014-11-17 | 2017-10-27 | 金陵科技学院 | A kind of probiotic microcapsule and preparation method added with prebiotics |
| CN104431354A (en) * | 2014-11-17 | 2015-03-25 | 金陵科技学院 | Probiotic microcapsules as well as preparation method and application thereof |
| CN105310080B (en) * | 2015-10-26 | 2018-04-06 | 中山大学 | Probiotic microcapsule and its preparation method and application |
| CN106723233B (en) * | 2016-11-28 | 2019-03-12 | 沈阳师范大学 | Using protein masses-polysaccharide as the probiotic microcapsule of wall material and preparation method |
| CN106617093B (en) * | 2016-12-30 | 2020-11-17 | 广州新济药业科技有限公司 | Acid-resistant and stable probiotic microcapsule and preparation method and application thereof |
| CN106993813B (en) * | 2017-03-31 | 2020-05-15 | 宝健（北京）生物技术有限公司 | Preparation method of probiotic microcapsules |
| CN112210511A (en) * | 2020-10-10 | 2021-01-12 | 内蒙古普泽生物制品有限责任公司 | Bifidobacterium longum with functions of inhibiting HT-29 cell proliferation and benefiting life and application thereof |
| CN112544978B (en) * | 2020-12-01 | 2023-10-03 | 上海扬彩生物科技有限公司 | Microcapsule-embedded probiotics capable of being released at fixed points in intestinal tracts and preparation method thereof |
| CN113289559B (en) * | 2021-06-04 | 2022-03-25 | 中国农业大学 | Nano microcapsule embedding hydrophilic compound and preparation method and application thereof |
| CN113854361B (en) * | 2021-10-08 | 2023-12-22 | 福建技术师范学院 | Freeze-dried strawberry probiotic milk beans with core-shell structure and preparation method thereof |
| CN114343186A (en) * | 2021-12-23 | 2022-04-15 | 安徽九鑫药业有限公司 | Probiotics capsule for promoting enterokinesia |
| CN114292781B (en) * | 2021-12-28 | 2023-08-01 | 中山大学 | Bifidobacterium longum SYSU-02 and application thereof |
| CN114747769B (en) * | 2022-02-25 | 2023-07-21 | 浙江旅游职业学院 | Probiotic product and preparation method thereof |
| CN115251393B (en) * | 2022-07-05 | 2024-02-27 | 上海菌小宝健康科技有限公司 | Probiotic microcapsule for improving intestinal flora and preparation method thereof |
| CN115624180B (en) * | 2022-09-09 | 2024-04-12 | 合生元（广州）健康产品有限公司 | Probiotics microcapsule containing osteopontin and preparation method thereof |
| CN115581657A (en) * | 2022-10-29 | 2023-01-10 | 上海加新生物科技有限公司 | Bifidobacterium longum composition and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101597604A (en) * | 2009-05-06 | 2009-12-09 | 任发政 | A kind of preparation method of micro-encapsulation bifidobacteria |
| CN101724623A (en) * | 2009-12-14 | 2010-06-09 | 内蒙古农业大学 | Lactobacillus casei Zhang microcapsule, preparation method and applications thereof |
| CN102210659A (en) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | Bifidobacterium microcapsule and preparing method thereof |
| CN103169140A (en) * | 2012-12-27 | 2013-06-26 | 北京中天神舟航天食品技术研究院 | Edible microcapsule for indicating probiotics activity and preparation method and application thereof |
| CN103721654A (en) * | 2012-10-12 | 2014-04-16 | 东北林业大学 | Technical condition of complex coacervation preparation of Juglans mandshurica Maxim oil microcapsule |
-
2014
- 2014-04-22 CN CN201410162678.XA patent/CN103932186B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101597604A (en) * | 2009-05-06 | 2009-12-09 | 任发政 | A kind of preparation method of micro-encapsulation bifidobacteria |
| CN101724623A (en) * | 2009-12-14 | 2010-06-09 | 内蒙古农业大学 | Lactobacillus casei Zhang microcapsule, preparation method and applications thereof |
| CN102210659A (en) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | Bifidobacterium microcapsule and preparing method thereof |
| CN103721654A (en) * | 2012-10-12 | 2014-04-16 | 东北林业大学 | Technical condition of complex coacervation preparation of Juglans mandshurica Maxim oil microcapsule |
| CN103169140A (en) * | 2012-12-27 | 2013-06-26 | 北京中天神舟航天食品技术研究院 | Edible microcapsule for indicating probiotics activity and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 双歧杆菌微胶囊化的研究进展;周冠华 等;《广州食品工业科技》;20040630;第20卷;第82-84页 * |
| 益生菌微胶囊化壁材与方法的研究进展;陈超 等;《食品工业科技》;20120229;第33卷(第14期);第403-407页 * |
| 长双歧杆菌BBMN68冷冻保护剂筛选与优化;刘松玲 等;《农业机械学报》;20100425;第41卷(第4期);第140-144页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103932186A (en) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103932186B (en) | A kind of bifidus longum bb microcapsule and preparation method thereof | |
| CN109619593B (en) | Probiotic double-layer microcapsule and preparation method thereof | |
| Liao et al. | Oligosaccharides as co-encapsulating agents: effect on oral Lactobacillus fermentum survival in a simulated gastrointestinal tract | |
| Mirzaei et al. | Effect of calcium alginate and resistant starch microencapsulation on the survival rate of Lactobacillus acidophilus La5 and sensory properties in Iranian white brined cheese | |
| CN102210659B (en) | Bifidobacterium microcapsule and preparing method thereof | |
| CN103109930B (en) | Fruity probiotic yogurt slice containing antifreeze sericin peptide and method for preparing same | |
| Li et al. | Microencapsulation of a probiotic bacteria with alginate–gelatin and its properties | |
| D’Orazio et al. | Microencapsulation of new probiotic formulations for gastrointestinal delivery: in vitro study to assess viability and biological properties | |
| Grosso et al. | Stability of free and immobilized Lactobacillus acidophilus and Bifidobacterium lactis in acidified milk and of immobilized B. lactis in yoghurt | |
| CN103169140B (en) | Edible microcapsule for indicating probiotics activity and preparation method and application thereof | |
| CN101724622B (en) | Method for preparing Lactobacillus casei microcapsule | |
| CN106418547A (en) | Probiotics microcapsule and preparation method thereof | |
| CN105567669B (en) | Probiotic microcapsule preparation and preparation method thereof | |
| Xing et al. | Effect of porous starch concentrations on the microbiological characteristics of microencapsulated Lactobacillus acidophilus | |
| Varankovich et al. | Survival of probiotics in pea protein-alginate microcapsules with or without chitosan coating during storage and in a simulated gastrointestinal environment | |
| CN101971920B (en) | Porcine lactobacillus reuteri lyophilized preparation and preparation method thereof | |
| Santacruz et al. | Viability of free and encapsulated Lactobacillus acidophilus incorporated to cassava starch edible films and its application to Manaba fresh white cheese | |
| CN104388416A (en) | Preparation method of microporous starch embedded lactic acid bacteria | |
| CN106617093A (en) | Acid-resistant and stable probiotic microcapsule as well as preparation method and application thereof | |
| CN109303166A (en) | The preparation method of heat resistance lactobacillus micro-capsule | |
| CN114916675A (en) | Water-in-oil-in-water type multiple emulsion gel bead for improving survival rate of probiotics, preparation method and application | |
| CN102077932A (en) | Method for preparing nutritional jelly rich in highly active intestinal probiotics | |
| CN105230782A (en) | Preparation method of hair weed yoghourt | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| Rezaei et al. | Preparation of milk‐based probiotic lactic acid bacteria biofilms: A new generation of probiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Leng Xiaojing Inventor after: Di Xiaona Inventor after: Liu Yun Inventor after: Yang Lifang Inventor after: Du Bingjian Inventor after: Liu Fei Inventor after: Zhang Chunyue Inventor after: Tang Xiaoshuang Inventor after: Ma Jing Inventor before: Leng Xiaojing Inventor before: Liu Yun Inventor before: Di Xiaona Inventor before: Yang Lifang Inventor before: Du Bingjian Inventor before: Liu Fei Inventor before: Zhang Chunyue Inventor before: Tang Xiaoshuang Inventor before: Ma Jing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LENG XIAOJING LIU YUN ZHAI XIAONA YANG LIFANG DU BINGJIAN LIU FEI ZHANG CHUNYUE TANG XIAOSHUANG MA JING TO: LENG XIAOJING ZHAI XIAONA LIU YUN YANG LIFANG DU BINGJIAN LIU FEI ZHANG CHUNYUE TANG XIAOSHUANG MA JING |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160330 Termination date: 20170422 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |